Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

365
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
365
Tumor Immunotherapy01:27

Tumor Immunotherapy

509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

886
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
886
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. The Impact Of Proton Pump Inhibitors On The Efficacy Of Immune Checkpoint Inhibitor Combinations In Patients With Hbv-associated Advanced Hepatocellular Carcinoma.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. The Impact Of Proton Pump Inhibitors On The Efficacy Of Immune Checkpoint Inhibitor Combinations In Patients With Hbv-associated Advanced Hepatocellular Carcinoma.

Related Experiment Video

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

The Impact of Proton Pump Inhibitors on the Efficacy of Immune Checkpoint Inhibitor Combinations in Patients with HBV-Associated Advanced Hepatocellular Carcinoma.

Ningning Wang1, Yuanyuan Xu1, Guangde Yang1

  • 1Department of Infectious Disease, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.

Journal of Hepatocellular Carcinoma
|July 9, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
chronic hepatitis B virus infectionhepatocellular carcinomaimmune checkpoint inhibitorsproton pump inhibitors

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

321

Related Experiment Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

321

Proton Pump Inhibitors (PPIs) generally do not affect survival for advanced hepatocellular carcinoma (HCC) patients on immune checkpoint inhibitors (ICIs). However, PPIs increase mortality risk in HCC patients with high HBV DNA levels, necessitating intensified antiviral therapy.

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is a significant global health concern.
  • Immune checkpoint inhibitors (ICIs) have revolutionized HCC treatment.
  • The impact of Proton Pump Inhibitors (PPIs) on ICI efficacy in HCC remains unclear.

Purpose of the Study:

  • To investigate the effect of PPIs on the survival outcomes of patients with HBV-associated advanced HCC undergoing ICI combination therapy.
  • To assess the safety profile of PPIs in conjunction with ICIs for HCC treatment.

Main Methods:

  • Retrospective analysis of 183 patients with HBV-associated advanced HCC treated with ICIs combination therapy.
  • Stratification into PPI and non-PPI groups based on PPI use within 30 days of ICI therapy.
  • Assessment of survival, mortality risk, and adverse events, including propensity score matching.

    • Main Results:

    • No significant difference in median survival time or adverse event incidence between PPI and non-PPI groups.
    • Propensity score matching confirmed no significant difference in overall survival (OS).
    • Subgroup analysis revealed PPI use significantly increased mortality risk in patients with HBV DNA ≥ 200 IU/mL (P=0.024).

    Conclusions:

    • PPIs do not significantly impact overall survival for HBV-associated advanced HCC patients receiving ICI therapy.
    • PPI use is associated with increased mortality risk in patients with high HBV DNA levels (≥ 200 IU/mL).
    • Intensified antiviral therapy is recommended for HCC patients with high HBV DNA levels receiving ICIs and PPIs.